The Zhangjiang AI New Drug R&D Alliance has welcomed new participants, including Regor Therapeutics, Roche, Hengrui Pharmaceuticals, Wuxi Biologics, LianBio, Baidu, Ainnocence, Galixir, Nutshell Therapeutics, Infinite Intelligence Pharma, and more. This expansion marks a significant step in enhancing the collaborative research efforts within the alliance.
Alliance Overview
The joint effort, initiated by academicians Chen Kaixian, Jiang Hualiang, and Rao Zihe, aims to advance key projects through collaborative research. The alliance is designed to foster the development of a local innovative ecosystem, leveraging the combined strengths of leading biotech and AI companies.
Future Implications
The addition of these new members underscores the growing importance of AI and biotechnology in drug development. By bringing together diverse expertise, the Zhangjiang AI New Drug R&D Alliance is positioned to accelerate the discovery and development of innovative therapies, contributing to advancements in global healthcare.-Fineline Info & Tech
